As demand for exome sequencing continues to grow, Eurofins Biomnis is acquiring another state-of-the-art sequencer developed by Illumina.
In 2020, to cope with an initial jump in exome sequencing orders, Eurofins Biomnis invested in a NextSeq 2000 to significantly increase its monthly capacity to more than 500 samples.
Today, in view of the number of direct samples received and forecasted demand, this capacity is no longer sufficient. For this reason, Eurofins Biomnis has confirmed its confidence in Illumina by acquiring a new system from this company: the Novaseq.
This sequencer has innovative design features, advanced technology, and simplified, integrated bioinformatics for rapid secondary analysis in both exome and genome analysis.
From September, this new piece of equipment, initially dedicated solely to exome analysis, will increase the capacity of the laboratory teams to process samples by up to 60%, while still ensuring optimum results and turnaround times.
In fact, completing all orders as soon as possible is one of our ultimate objectives at Eurofins Biomnis. Today, the results of an exome test are returned within 6 weeks for postnatal and within 4 weeks for prenatal tests. However, with the integration of this new equipment, our the laboratory teams hope to be in a position to offer even more highly optimised turnaround times in the very near future.
Thanks to Novaseq and the technical expertise of Illumina, Eurofins Biomnis is helping to make exome sequencing more accessible and continues to innovate in the field of genomics.
For more information
“Focus on…” Exome sequencing in genetic diseases (ref. DS34-INTGB)
